Conference Coverage

Intensified rifampicin boosts outcomes in TB/HIV coinfection

Publish date: August 13, 2016

 

AT AIDS 2016

References

The trial was funded by the European and Developing Countries Clinical Trials Partnership. Dr. Merle reported having no financial conflicts of interest.

bjancin@frontlinemedcom.com

Pages

Recommended Reading

New HIV antiretroviral guidelines embrace PrEP, early ART
MDedge Infectious Disease
HIV research update: Late July 2016
MDedge Infectious Disease
Starting antiretroviral therapy on same day as HIV testing improves outcomes
MDedge Infectious Disease
HIV chemoprophylaxis in U.S. up 738% in recent 3-year period
MDedge Infectious Disease
HIV chemoprophylaxis shown effective in 15-year-olds
MDedge Infectious Disease
Changes in HIV-related cancers reflect changes in HIV patient care
MDedge Infectious Disease
CMV viremia not culprit in high mortality of TB/HIV coinfection
MDedge Infectious Disease
Don’t delay treatment for patients with TB and HIV
MDedge Infectious Disease
Monitoring renal function during daily oral HIV PrEP
MDedge Infectious Disease
HIV-related lymphoma rate remains sky-high despite ART
MDedge Infectious Disease